110 related articles for article (PubMed ID: 19723128)
21. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis.
Thiel MA; Zinkernagel AS; Burhenne J; Kaufmann C; Haefeli WE
Antimicrob Agents Chemother; 2007 Jan; 51(1):239-44. PubMed ID: 17060517
[TBL] [Abstract][Full Text] [Related]
22. Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration.
Fiscella RG; Lai WW; Buerk B; Khan M; Rodvold KA; Pulido JS; Labib S; Shapiro MJ; Blair NP
Ophthalmology; 2004 Jun; 111(6):1191-5. PubMed ID: 15177970
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of voriconazole after oral and intravenous administration to horses.
Davis JL; Salmon JH; Papich MG
Am J Vet Res; 2006 Jun; 67(6):1070-5. PubMed ID: 16740104
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis.
Kernt M; Neubauer AS; De Kaspar HM; Kampik A
Retina; 2009 Mar; 29(3):362-70. PubMed ID: 18997637
[TBL] [Abstract][Full Text] [Related]
25. Stability of extemporaneously prepared voriconazole ophthalmic solution.
Al-Badriyeh D; Li J; Stewart K; Kong DC; Leung L; Davies GE; Fullinfaw R
Am J Health Syst Pharm; 2009 Aug; 66(16):1478-83. PubMed ID: 19667005
[TBL] [Abstract][Full Text] [Related]
26. Impact of corneal cross-linking on drug penetration in an ex vivo porcine eye model.
Tschopp M; Stary J; Frueh BE; Thormann W; De Smet J; Van Bocxlaer J; Tappeiner C
Cornea; 2012 Mar; 31(3):222-6. PubMed ID: 22316648
[TBL] [Abstract][Full Text] [Related]
27. Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans.
Senthilkumari S; Lalitha P; Prajna NV; Haripriya A; Nirmal J; Gupta P; Velpandian T
Curr Eye Res; 2010 Nov; 35(11):953-60. PubMed ID: 20958183
[TBL] [Abstract][Full Text] [Related]
28. [Ocular penetration and pharmacokinetics of topical voriconazole in rabbit eyes].
Sun MX; Chen JQ; Yao MC; Ye CT; Li J; Huang MM
Zhonghua Yan Ke Za Zhi; 2008 Apr; 44(4):349-53. PubMed ID: 18844023
[TBL] [Abstract][Full Text] [Related]
29. Endogenous Scedosporium apiospermum endophthalmitis.
Jain A; Egbert P; McCulley TJ; Blumenkranz MS; Moshfeghi DM
Arch Ophthalmol; 2007 Sep; 125(9):1286-9. PubMed ID: 17846376
[No Abstract] [Full Text] [Related]
30. Unusual pharmacokinetics of intravitreal and systemic voriconazole in a patient with Scedosporium apiospermum endophthalmitis.
Nochez Y; Arsene S; Le Guellec C; Bastides F; Morange V; Chaumais MC; Pisella PJ
J Ocul Pharmacol Ther; 2008 Feb; 24(1):87-90. PubMed ID: 18370878
[TBL] [Abstract][Full Text] [Related]
31. Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.
Puustjärvi T; Teräsvirta M; Nurmenniemi P; Lokkila J; Uusitalo H
Graefes Arch Clin Exp Ophthalmol; 2006 Dec; 244(12):1633-7. PubMed ID: 16715252
[TBL] [Abstract][Full Text] [Related]
32. Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients.
Gómez-López A; Cendejas-Bueno E; Cuesta I; García Rodríguez J; Rodríguez-Tudela JL; Gutiérrez-Altés A; Cuenca-Estrella M
Med Mycol; 2012 May; 50(4):439-45. PubMed ID: 22070341
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of voriconazole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses.
Colitz CM; Latimer FG; Cheng H; Chan KK; Reed SM; Pennick GJ
Am J Vet Res; 2007 Oct; 68(10):1115-21. PubMed ID: 17916020
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in African grey parrots (Psittacus erithacus timneh).
Flammer K; Nettifee Osborne JA; Webb DJ; Foster LE; Dillard SL; Davis JL
Am J Vet Res; 2008 Jan; 69(1):114-21. PubMed ID: 18167096
[TBL] [Abstract][Full Text] [Related]
35. In vivo efficacy and pharmacokinetics of voriconazole in an animal model of dermatophytosis.
Saunte DM; Simmel F; Frimodt-Moller N; Stolle LB; Svejgaard EL; Haedersdal M; Kloft C; Arendrup MC
Antimicrob Agents Chemother; 2007 Sep; 51(9):3317-21. PubMed ID: 17576826
[TBL] [Abstract][Full Text] [Related]
36. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.
Hariprasad SM; Shah GK; Chi J; Prince RA
J Cataract Refract Surg; 2005 Nov; 31(11):2142-6. PubMed ID: 16412929
[TBL] [Abstract][Full Text] [Related]
37. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
38. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients.
Rüping MJ; Müller C; Vehreschild JJ; Böhme A; Mousset S; Harnischmacher U; Frommolt P; Wassmer G; Drzisga I; Hallek M; Cornely OA
Mycoses; 2011 May; 54(3):230-3. PubMed ID: 19889174
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics, tissue concentrations, and safety of the antifungal agent voriconazole in chickens.
Burhenne J; Haefeli WE; Hess M; Scope A
J Avian Med Surg; 2008 Sep; 22(3):199-207. PubMed ID: 19014092
[TBL] [Abstract][Full Text] [Related]
40. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.
Ottiger M; Thiel MA; Feige U; Lichtlen P; Urech DM
Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):779-86. PubMed ID: 18757511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
